Biohaven Pharmaceutical Holding Company Ltd.

NYSE BHVN

Biohaven Pharmaceutical Holding Company Ltd. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -848.89 M

Biohaven Pharmaceutical Holding Company Ltd. Operating Income is USD -848.89 M for the Trailing 12 Months (TTM) ending September 30, 2024. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.
  • Biohaven Pharmaceutical Holding Company Ltd. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -405.40 M, a 36.03% change year over year.
  • Biohaven Pharmaceutical Holding Company Ltd. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -633.76 M, a -3.95% change year over year.
  • Biohaven Pharmaceutical Holding Company Ltd. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -609.68 M.
Key data
Date Operating Income EBIT EBITDA Net Income
Market news
Loading...
NYSE: BHVN

Biohaven Pharmaceutical Holding Company Ltd.

CEO Dr. Vladimir Coric M.D.
IPO Date Sept. 23, 2022
Location United States
Headquarters 215 Church Street
Employees 239
Sector Health Care
Industries
Description

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Similar companies

IMNM

Immunome, Inc.

USD 9.38

-6.57%

INZY

Inozyme Pharma, Inc.

USD 1.51

-12.21%

MREO

Mereo BioPharma Group plc

USD 3.06

-8.38%

RVMD

Revolution Medicines, Inc.

USD 39.83

-6.44%

TERN

Terns Pharmaceuticals, Inc.

USD 4.57

-4.79%

KYMR

Kymera Therapeutics, Inc.

USD 40.12

7.79%

APLS

Apellis Pharmaceuticals, Inc.

USD 27.69

-3.15%

DAWN

Day One Biopharmaceuticals, Inc.

USD 11.16

-3.46%

CCCC

C4 Therapeutics, Inc.

USD 3.74

6.86%

AGIO

Agios Pharmaceuticals, Inc.

USD 33.32

-2.86%

BPMC

Blueprint Medicines Corporation

USD 102.56

-0.77%

AMLX

Amylyx Pharmaceuticals, Inc.

USD 3.13

-1.57%

INBX

Inhibrx Biosciences, Inc.

USD 12.74

-6.60%

NRIX

Nurix Therapeutics, Inc.

USD 18.60

-2.16%

StockViz Staff

January 15, 2025

Any question? Send us an email